Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Pharmaxis Ltd ( (AU:SNT) ) just unveiled an announcement.
Syntara Limited, a clinical-stage drug development company, has announced positive interim data from its Phase 2 clinical trial of SNT-5505 in combination with ruxolitinib for treating myelofibrosis. The results, to be presented at the European Hematology Association Conference, show significant improvements in patient symptoms and spleen volume, highlighting SNT-5505’s potential to change long-term outcomes for myelofibrosis patients. The drug has demonstrated a good safety profile with no serious adverse events, and the company plans to engage with the FDA for further study designs.
The most recent analyst rating on (AU:SNT) stock is a Buy with a A$0.25 price target. To see the full list of analyst forecasts on Pharmaxis Ltd stock, see the AU:SNT Stock Forecast page.
More about Pharmaxis Ltd
Average Trading Volume: 8,136,081
Technical Sentiment Signal: Buy
Current Market Cap: A$112.1M
For a thorough assessment of SNT stock, go to TipRanks’ Stock Analysis page.